Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department plans to make an assessment of the effectiveness of immunotherapy as a treatment for brain cancer; and if he will make a statement.

The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance for the National Health Service on whether medicines represent a clinically and cost-effective use of resources. All new medicines, including immunotherapies, are appraised by NICE within their licensed indications, and the NHS in England is legally required to fund medicines recommended by NICE.

NICE is currently developing guidance on the immunotherapy dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 to 17. If this is recommended for use on the NHS, it will be eligible for funding through the Cancer Drugs Fund from the point that NICE issues positive draft guidance.